NOACs May Be Better Choice for Patients With A-Fib and DM
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Atrial Fibrillation
USPSTF: Evidence Still Lacking for Atrial Fibrillation Screening
Evidence currently inadequate for assessing the balance of benefits and harms of screening for atrial fibrillation in asymptomatic adults
Marine Omega-3 Supplements Tied to Higher Atrial Fibrillation Risk
Risk appeared to be greater in trials testing >1 g/day dosing
FDA: Risk of LAAO Implant-Related Adverse Events May Be Higher for Women
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Noncompliance to Apixaban for A-Fib Due to Many Factors
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Individual A-Fib Episodes Tied to Recent Alcohol Intake
AF episodes also linked to higher odds of peak blood alcohol concentration, total area under curve of alcohol exposure
Non-Vitamin K Antagonist Oral Anticoagulants vs Warfarin in NVAF Patients
Findings may help with decision-making in this high-risk patient population.
Amplatzer Amulet Approved to Reduce Thromboembolic Risk in Atrial Fibrillation
The Amulet device is designed for complete immediate closure of the left atrial appendage using dual-seal technology.
Racial/Ethnic Disparities Seen in Anticoagulant Initiation for A-Fib
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
